Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its ...

Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...

Merck is particularly exposed to the tariff threat, as much of its production of Keytruda takes place at facilities in ...

It will build a Wilmington, Delaware facility dedicated to making its cancer drug, Keytruda, for U.S. patients.

Valued at $209.8 billion by market cap, Merck & Co., Inc. (MRK) is a global pharmaceutical powerhouse headquartered in Rahway ...

Immutep believes its LAG-3 candidate eftilagimod alpha may have a path to approval in first-line head and neck cancer after ...

According to Merck, the total investment is now expected to be over $1 billion, with 500 full-time jobs and 4,000 ...

A biotech company is suing to block Merck & Co. from launching an easier-to-use version of its blockbuster cancer treatment ...

The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.

Merck announced on Tuesday that it is investing $1 billion in a new Delaware plant to expand domestic production as it ...

U.S. drugmaker Merck said on Tuesday it is investing $1 billion in a new Delaware plant to expand domestic production as it ...